Provectus Biopharmaceuticals, Inc.
PVCT
$0.05
$0.00-0.75%
OTC PK
| 06/30/2026 | 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | |
|---|---|---|---|---|---|
| Revenue | 0.00 | 57.50K | 336.10K | 350.40K | 460.10K |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 0.00 | 57.50K | 336.10K | 350.40K | 460.10K |
| Cost of Revenue | 991.10K | 1.74M | 1.81M | 2.11M | 2.19M |
| Gross Profit | -991.10K | -1.68M | -1.48M | -1.76M | -1.73M |
| SG&A Expenses | 3.25M | 3.38M | 3.44M | 4.36M | 3.99M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 4.30M | 5.17M | 5.30M | 6.56M | 6.26M |
| Operating Income | -4.30M | -5.12M | -4.97M | -6.21M | -5.80M |
| Income Before Tax | -4.78M | -5.64M | -5.51M | -6.73M | -6.43M |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -4.78 | -5.64 | -5.51 | -6.73 | -6.43 |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | 31.80K | 63.30K | 74.30K | 101.10K | 88.80K |
| Net Income | -4.75M | -5.58M | -5.43M | -6.63M | -6.34M |
| EBIT | -4.30M | -5.12M | -4.97M | -6.21M | -5.80M |
| EBITDA | -4.30M | -5.11M | -4.96M | -6.21M | -5.80M |
| EPS Basic | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Basic EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| EPS Diluted | -0.01 | -0.01 | -0.01 | -0.02 | -0.02 |
| Normalized Diluted EPS | -0.01 | -0.01 | -0.01 | -0.01 | -0.01 |
| Average Basic Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Average Diluted Shares Outstanding | 1.68B | 1.68B | 1.68B | 1.68B | 1.68B |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |